Berenberg Bank Initiates Coverage on Athira Pharma (NASDAQ:ATHA)

Equities researchers at Berenberg Bank assumed coverage on shares of Athira Pharma (NASDAQ:ATHAGet Rating) in a research report issued on Thursday, Briefing.com reports. The firm set a “buy” rating and a $33.00 price target on the stock. Berenberg Bank’s price objective suggests a potential upside of 183.75% from the company’s current price.

Other equities research analysts have also issued reports about the company. JMP Securities reaffirmed a “buy” rating and issued a $51.00 target price on shares of Athira Pharma in a research report on Friday, March 25th. Zacks Investment Research raised Athira Pharma from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Tuesday, March 29th.

ATHA stock opened at $11.63 on Thursday. The firm has a market cap of $437.57 million, a P/E ratio of -8.19 and a beta of 3.56. Athira Pharma has a 12-month low of $8.51 and a 12-month high of $23.64. The stock’s 50 day simple moving average is $10.79 and its 200 day simple moving average is $11.72.

Athira Pharma (NASDAQ:ATHAGet Rating) last posted its quarterly earnings results on Thursday, March 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.09. During the same period last year, the business earned ($0.24) EPS. On average, equities research analysts forecast that Athira Pharma will post -2.49 earnings per share for the current fiscal year.

In other Athira Pharma news, Director Kelly A. Romano purchased 8,000 shares of the firm’s stock in a transaction dated Thursday, March 31st. The stock was bought at an average price of $13.11 per share, with a total value of $104,880.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 14.90% of the company’s stock.

Several large investors have recently added to or reduced their stakes in ATHA. Morgan Stanley grew its stake in shares of Athira Pharma by 30.4% in the first quarter. Morgan Stanley now owns 22,445 shares of the company’s stock worth $413,000 after purchasing an additional 5,230 shares in the last quarter. Bank of America Corp DE boosted its stake in Athira Pharma by 56.3% during the second quarter. Bank of America Corp DE now owns 16,749 shares of the company’s stock valued at $172,000 after buying an additional 6,036 shares in the last quarter. SG Americas Securities LLC bought a new position in Athira Pharma during the third quarter valued at about $182,000. EMC Capital Management boosted its stake in Athira Pharma by 22.1% during the third quarter. EMC Capital Management now owns 26,487 shares of the company’s stock valued at $346,000 after buying an additional 4,791 shares in the last quarter. Finally, Deutsche Bank AG boosted its stake in Athira Pharma by 67.1% during the third quarter. Deutsche Bank AG now owns 38,480 shares of the company’s stock valued at $361,000 after buying an additional 15,449 shares in the last quarter. 66.91% of the stock is owned by institutional investors.

About Athira Pharma (Get Rating)

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease.

Featured Stories

Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.